Octapharma Ag

Werner Gehringer

Petra Schulz

Rainer Pape

Jürgen Römisch

Friedrich Schön

Caroline Leitinger

Horst Schwinn

Djuro Josic

Monika Stadler

Frederic Bal

Katharina Pock

Patrick Selosse

A process for purifying fibrinogen from a fibrinogen containing source by precipitation of fibrinogen by a precipitating agent from a fibrinogen containing solution in the presence of one or more chelating agent(s) and removal of the supernatant from the fibrinogen paste, characterised in that fibrinogen is extracted from the paste forming a liquid fraction containing fibrinogen, and an undissolved residue, which is separated from the liquid.

Process for production of fibrinogen and fibrinogen produced thereby

A process for purifying fibrinogen from a fibrinogen containing source by precipitation of fibrinogen by a precipitating agent from a fibrinogen containing solution in the presence of one or more chelating agent(s) and removal of the supernatant from the fibrinogen paste, characterized in that fibrinogen is extracted from the paste forming a liquid fraction containing fibrinogen, and an undissolved residue, which is separated from the liquid.

The present invention relates to a method or process for the manufacture of a virus and prion save native fibrinogen concentrate of high purity and low amounts of fibrinopeptide A and fibronectin.

Process for production of fibrinogen

An albumin containing fraction having a reduced prekallikrein activator (PKA) content and a method of manufacturing same comprising the steps of:

Prekallikrein depleted plasma derived albumin fraction

A method for the inactivation of viruses, in particular those having no lipid coats, in protein-containing compositions from blood, blood plasma or similar natural sources by treating said source, simultaneously or succesively, with an effective amount of dialkyl or trialkyl phosphates and optionally surfactants at an elevated temperature in the range of from 55&deg; C. to 67&deg; C. for five hours to 30 hours.

Method for the inactivation of non-lipid-coated viruses

This invention describes a process for preparing virus-inactivated immunoglobulin solutions suitable for intra-venous application, characterized in that the immunoglobulin is treated with non-ionic surfactants which subsequently are removed by solid-phase extraction on hydrophobic materials.

Growing community of inventors

Vienna, Austria

Werner Gehringer